The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Effects of an Oral Growth Hormone Secretagogue in Older Adults
Open accessAbstract
CONTEXT: GH secretion declines with age, possibly contributing to reduced muscle mass, strength, and function. GH secretagogues (GHS) may increase muscle mass and physical performance. OBJECTIVES/DESIGN: We conducted a randomized, double-masked, placebo-controlled, multicenter study to investigate the hormonal, body composition, and physical performance effects and the safety of the orally active GHS capromorelin in older adults with mild functional limitation. INTERVENTION/PARTICIPANTS: A total of 395 men and women aged 65-84 yr were randomized for an intended 2 yr of treatment to four dosing groups (10 mg three times/week, 3 mg twice a day, 10 mg each night, and 10 mg twice a day) or placebo. Although the study was terminated early according to predetermined treatment effect criteria, 315 subjects completed 6 months of treatment, and 284 completed 12 months. RESULTS: A sustained dose-related rise in IGF-I concentrations occurred in all active treatment groups. Each capromorelin dose prompted a rise in peak nocturnal GH, which was greatest with the least frequent dosing. At 6 months, body weight increased 1.4 kg in subjects receiving capromorelin and decreased 0.2 kg in those receiving placebo (P = 0.006). Lean body mass increased 1.4 vs. 0.3 kg (P = 0.001), and tandem walk improved by 0.9 sec (P = 0.02) in the pooled treatment vs. placebo groups. By 12 months, stair climb also improved (P = 0.04). Adverse events included fatigue, insomnia, and small increases in fasting glucose, glycosylated hemoglobin, and indices of insulin resistance. CONCLUSIONS: In healthy older adults at risk for functional decline, administration of the oral GHS capromorelin may improve body composition and physical function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development and validation of a geriatric depression screening scale: a preliminary report
Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90033-4 · Cited by 15,025 · cited 1×
“Health status measures included the SF-36 Health Survey (28), MiniMental Status Exam (29), Geriatric Depression Scale (30), Nagi’s Instrumental Activities of Daily Living (22), Medical Outcomes StudySleep Scale (MOS-SS) Index II (31), and Physical Activity Index (PAI) (32).”
MethodGuralnik, J. M., Simonsick, E. M., Ferrucci, L., Glynn, R. J., Berkman, L. F., Blazer, D. G., Scherr, P. A., & Wallace, R. B. (1994) · Journal of Gerontology · doi:10.1093/geronj/49.2.m85 · Cited by 9,792
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999) · Nature · doi:10.1038/45230 · Cited by 8,479
Compendium of Physical Activities: Classification of energy costs of human physical activities
AINSWORTH, B. E., HASKELL, W. L., LEON, A. S., JACOBS, D. R., MONTOYE, H. J., SALLIS, J. F., & PAFFENBARGER, R. S. (1993) · Medicine & Science in Sports & Exercise · doi:10.1249/00005768-199301000-00011 · Cited by 4,102
Exercise training and nutritional supplementation for physical frailty in very elderly people
Fiatarone, M. A., O'Neill, E. F., Ryan, N. D., Clements, K. M., Solares, G. R., Nelson, M. E., Roberts, S. B., Kehayias, J. J., Lipsitz, L. A., & Evans, W. J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406233302501 · Cited by 2,857
Measuring Functioning and Well-Being: The Medical Outcomes Study Approach
Stewart, A., & Ware, J. (1992) · doi:10.7249/cb361 · Cited by 2,689
Muniyappa, R., Lee, S., Chen, H., & Quon, M. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00645.2007 · Cited by 1,643 · cited 1×
“5 , were calculated to determine the diabetogenic potential of capromorelin (33, 34).”
BackgroundBiological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin
van der Lely, A. J., Tschöp, M., Heiman, M. L., & Ghigo, E. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0029 · Cited by 1,187
HO, K. Y., EVANS, W. S., BLIZZARD, R. M., VELDHUIS, J. D., MERRIAM, G. R., SAMOJLIK, E., FURLANETTO, R., ROGOL, A. D., KAISER, D. L., & THORNER, M. O. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-1-51 · Cited by 921
Human growth hormone and human aging
CORPAS, E., HARMAN, S. M., & BLACKMAN, M. R. (1993) · Endocrine Reviews · doi:10.1210/edrv-14-1-20 · Cited by 911 · cited 1×
“GH secretion decreases progressively between the ages of 30 and 70 yr (3, 4), as does the serum concentration of IGF-I (5, 6).”
BackgroundSelf-citation
Cited by
Cardoso, A. L., Fernandes, A., Aguilar-Pimentel, J. A., de Angelis, M. H., Guedes, J. R., Brito, M. A., Ortolano, S., Pani, G., Athanasopoulou, S., Gonos, E. S., et al. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.07.004 · Cited by 475
Sarcopenia, Cachexia and Aging: Diagnosis, Mechanisms and Therapeutic Options - A Mini-Review
Ali, S., & Garcia, J. M. (2014) · Gerontology · doi:10.1159/000356760 · Cited by 462
Ghrelin in the regulation of body weight and metabolism
Castañeda, T. R., Tong, J., Datta, R., Culler, M., & Tschöp, M. H. (2010) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2009.10.008 · Cited by 352
A review of sarcopenia: Enhancing awareness of an increasingly prevalent disease
Marty, E., Liu, Y., Samuel, A., Or, O., & Lane, J. (2017) · Bone · doi:10.1016/j.bone.2017.09.008 · Cited by 288
Pharmacologic Options for the Treatment of Sarcopenia
Morley, J. E. (2016) · Calcified Tissue International · doi:10.1007/s00223-015-0022-5 · Cited by 225
“Capromorelin, a ghrelin receptor agonist, was tested in older sarcopenic individuals [144].”
BackgroundCurrent and investigational medications for the treatment of sarcopenia
Rolland, Y., Dray, C., Vellas, B., & Barreto, P. D. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155597 · Cited by 195
the Sarcopenia Guidelines Development group of the Belgian Society of Gerontology and Geriatrics (BSGG), De Spiegeleer, A., Beckwée, D., Bautmans, I., & Petrovic, M. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0566-y · Cited by 160
Sarcopenic obesity: how do we treat it?
Bouchonville, M. F., & Villareal, D. T. (2013) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/01.med.0000433071.11466.7f · Cited by 141
Fujitsuka, N., Asakawa, A., Morinaga, A., Amitani, M. S., Amitani, H., Katsuura, G., Sawada, Y., Sudo, Y., Uezono, Y., Mochiki, E., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.220 · Cited by 114
Therapies for Musculoskeletal Disease: Can we Treat Two Birds with One Stone?
Girgis, C. M., Mokbel, N., & DiGirolamo, D. J. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0204-5 · Cited by 110
Bhattacharya, S. K., Andrews, K., Beveridge, R., Cameron, K. O., Chen, C., Dunn, M., Fernando, D., Gao, H., Hepworth, D., Jackson, V. M., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400473x · Cited by 73
Adunsky, A., Chandler, J., Heyden, N., Lutkiewicz, J., Scott, B. B., Berd, Y., Liu, N., & Papanicolaou, D. A. (2011) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2010.10.004 · Cited by 67
Muscle Wasting in Ageing and Chronic Illness
Ebner, N., Sliziuk, V., Scherbakov, N., & Sandek, A. (2015) · ESC Heart Failure · doi:10.1002/ehf2.12033 · Cited by 61
Liver-expressed antimicrobial peptide 2 elevation contributes to age-associated cognitive decline
Tian, J., Guo, L., Wang, T., Jia, K., Swerdlow, R. H., Zigman, J. M., & Du, H. (2023) · JCI Insight · doi:10.1172/jci.insight.166175 · Cited by 16
Metadata
- Authors
- White, H. K., Petrie, C. D., Landschulz, W., MacLean, D., Taylor, A., Lyles, K., Wei, J. Y., Hoffman, A. R., Salvatori, R., Ettinger, M. P., Morey, M. C., Blackman, M. R., Merriam, G. R., & for the Capromorelin Study Group
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-04-01
- Volume
- 94
- Issue
- 4
- Pages
- 1198-1206
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2141361742
- Cited by
- 171
- References
- 16
- FWCI
- 7.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.